Robert Martell
CIK 1529922 · View on SEC EDGAR ↗
First SEC filing: Jan. 24, 2023 · Latest: Jan. 24, 2023
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Jan. 23, 2019 | CRIS | S 10b5-1 | 5,500 | $1.07 | $5,885 | 23,027 Direct | -19.28% | Disposed | -99.6% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 20, 2023 | CRIS | Employee stock option (right to buy) | Common Stock (350,000) | $0.70 | Jan. 19, 2033 | 350,000 | Acquired |
| Jan. 29, 2022 | CRIS | Employee stock option (right to buy) | Common stock (252,000) | $3.09 | Jan. 28, 2032 | 252,000 | Acquired |
| Jan. 28, 2021 | CRIS | Employee stock option (right to buy) | Common stock (126,000) | $9.14 | Jan. 27, 2031 | 126,000 | Acquired |
| March 2, 2020 | CRIS | Employee stock option (right to buy) | Common stock (385,000) | $1.26 | March 1, 2030 | 385,000 | Acquired |
| May 23, 2019 | CRIS | Employee stock option (right to buy) | Common stock (386,996) | $1.16 | Jan. 20, 2029 | 386,996 | Acquired |
| June 1, 2018 | CRIS | Employee stock option (right to buy) | Common stock (303,000) | $2.49 | May 31, 2028 | 303,000 | Acquired |
| Feb. 28, 2017 | CRIS | Non-qualified stock option | Common Stock (120,000) | $2.31 | Feb. 27, 2027 | 120,000 | Acquired |
| Jan. 19, 2016 | CRIS | Non-qualified stock option | Common stock (50,000) | $1.76 | Jan. 19, 2026 | 50,000 | Acquired |
| Jan. 26, 2015 | CRIS | Non-qualified stock option (right to buy) | Common stock (25,000) | $1.94 | Jan. 26, 2025 | 25,000 | Acquired |
| Jan. 27, 2014 | CRIS | Non-qualified stock option (right to buy) | Common stock (25,000) | $2.94 | Jan. 27, 2024 | 25,000 | Acquired |
| Jan. 17, 2013 | CRIS | Non-qualified stock option (right to buy) | Common stock (25,000) | $3.32 | Jan. 17, 2023 | 25,000 | Acquired |
| Jan. 5, 2012 | CRIS | Non-qualified stock option (right to buy) | Common stock (25,000) | $4.52 | Jan. 5, 2022 | 50,000 | Acquired |
| Sept. 14, 2011 | CRIS | Non-qualified stock option (right to buy) | Common stock (25,000) | $3.36 | Sept. 14, 2021 | 25,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2021 | $370,508 | — | — | — | $198,186 | — | $17,400 | $1,502,517 |
| 2020 | $366,091 | — | — | — | $261,954 | — | $11,401 | $961,345 |
| 2018 | $186,712 | — | — | — | $124,688 | — | — | $914,426 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.